Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1999892 | 1.00 | ALDH1A1 (0.31) | ALDH1A1POLBMAPTKMT2ASMN1; SMN2 | |
| SCHEMBL1994634 | 0.81 | ALDH1A1 (0.36) | ALDH1A1POLBMAPTKMT2ASMN1; SMN2 | |
| SCHEMBL1999701 | 0.80 | ALDH1A1 (0.33) | ALDH1A1POLBMAPTKMT2ASMN1; SMN2 | |
| SCHEMBL1995088 | 0.76 | PDE4B (0.33) | ALDH1A1POLBMAPTKMT2ASMN1; SMN2 | |
| SCHEMBL1996484 | 0.75 | PDE4B (0.34) | ALDH1A1POLBMAPTKMT2ASMN1; SMN2 | |
| SCHEMBL1996481 | 0.75 | PDE4B (0.34) | ALDH1A1POLBMAPTKMT2ASMN1; SMN2 | |
| SCHEMBL1997382 | 0.75 | PDE4B (0.38) | ALDH1A1MAPTKMT2ASMN1; SMN2NPSR1 | |
| SCHEMBL1996657 | 0.74 | ALDH1A1 (0.46) | ALDH1A1NPSR1 | |
| SCHEMBL1994341 | 0.74 | MAPT (0.46) | ALDH1A1POLBMAPTKMT2ASMN1; SMN2 | |
| SCHEMBL1993161 | 0.71 | PDE4A (0.35) | ALDH1A1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7960383-B2 | phosphodiesterase enzyme inhibitor; 4-[(3-chlorophenyl)amino]-2-ethyl-5-(1-hydroxyethyl)-6-phenylpyridazin-3(2H)-one; potent antiinflammatory agent; asthma, atopic dermatitis, psoriasis, chronic obstructive pulmonary disease, rheumatoid arthritis, irritable bowel disease | LABORATORIOS ALMIRALL SA (ES) | 2011-06-14 | — | — | US | disclosed |
| EP-1758869-B1 | PYRIDAZIN-3(2H)-ONE DERIVATIVES AND THEIR USE AS PDE4 INHIBITORS | ALMIRALL SA (ES) | 2010-12-22 | — | — | EP | disclosed |
| US-20080280918-A1 | Pyridazin-3(2H)-One Derivatives and Their Use as Pde4 Inhibitors | ALMIRALL PRODESFARMA, SA (ES) | 2008-11-13 | — | — | US | disclosed |
| EP-1758869-A1 | PYRIDAZIN-3(2H)-ONE DERIVATIVES AND THEIR USE AS PDE4 INHIBITORS | Almirall Prodesfarma, S.A. (ES) | 2007-03-07 | — | — | EP | disclosed |
| WO-2005123692-A1 | PYRIDAZIN-3(2H)-ONE DERIVATIVES AND THEIR USE AS PDE4 INHIBITORS | LABORATORIOS ALMIRALL, S.A. (ES) | 2005-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280918-A1 | Pyridazin-3(2H)-One Derivatives and Their Use as Pde4 Inhibitors | PDE12, PDE4A, PDE4B | ALDH1A1 457/4885POLB 1003/4885MAPT 2663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.